A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda

A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda

Abstract Background While the combination of nifurtimox and eflornithine (NECT) is currently recommended for the treatment of the late stage human African trypansomiasis (HAT), single-agent eflornithine was still the treatment of choice when this trial commenced. This study intended to provide suppo...

Full description

Bibliographic Details
Main Authors: Freddie Kansiime, Seraphine Adibaku, Charles Wamboga, Franklin Idi, Charles Drago Kato, Lawrence Yamuah, Michel Vaillant, Deborah Kioy, Piero Olliaro, Enock Matovu
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Parasites & Vectors
Subjects:
Human African trypanosomiasis (HAT)
Meningo-encephalitic stage
Second-stage HAT
Nifurtimox-eflornithine combination treatment (NECT)
Online Access:http://link.springer.com/article/10.1186/s13071-018-2634-x

Internet

http://link.springer.com/article/10.1186/s13071-018-2634-x

Similar Items